@article {Matrajt2020.08.14.20175257, author = {Laura Matrajt and Julie Eaton and Tiffany Leung and Elizabeth R. Brown}, title = {Vaccine optimization for COVID-19, who to vaccinate first?}, elocation-id = {2020.08.14.20175257}, year = {2020}, doi = {10.1101/2020.08.14.20175257}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {A vaccine, when available, will likely become our best tool to control the current COVID-19 pandemic. Even in the most optimistic scenarios, vaccine shortages will likely occur. Using an age-stratified mathematical model, we determined optimal vaccine allocation for four different metrics (deaths, symptomatic infections, and maximum non-ICU and ICU hospitalizations) under a wide variety of assumptions. We find that a vaccine with effectiveness >=50\% would be enough to substantially mitigate the ongoing pandemic provided that a high percentage of the population is optimally vaccinated. When minimizing deaths, we find that for low vaccine effectiveness, it is optimal to allocate vaccine to high-risk (older) age-groups first. In contrast, for higher vaccine effectiveness, there is a switch to allocate vaccine to high-transmission (younger) age-groups first for high vaccination coverage. While there are other societal and ethical considerations, this work can provide an evidence-based rationale for vaccine prioritization.Competing Interest StatementThe authors have declared no competing interest.Funding StatementLM, TL and ERB acknowledge support from NIAID, grant 1 UM1 AI148684-01Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available in the manuscript. https://github.com/lulelita/vaccine_optimization}, URL = {https://www.medrxiv.org/content/early/2020/08/16/2020.08.14.20175257}, eprint = {https://www.medrxiv.org/content/early/2020/08/16/2020.08.14.20175257.full.pdf}, journal = {medRxiv} }